ETR
63
2
FMC
64
2
BWA
72
3
AIV
72
7
NAVI
44
4
M
45
5
BLK
44
3
VLO
68
3
EA
52
3
TJX
62
5
MAT
54
4
IFF
56
26
ABBV
71
3
CMCSA
34
3
O
47
2
COST
41
-7
MCK
45
-3
ACN
50
3
MAR
44
3
MU
40
-7
ETR
63
2
FMC
64
2
BWA
72
3
AIV
72
7
NAVI
44
4
M
45
5
BLK
44
3
VLO
68
3
EA
52
3
TJX
62
5
MAT
54
4
IFF
56
26
ABBV
71
3
CMCSA
34
3
O
47
2
COST
41
-7
MCK
45
-3
ACN
50
3
MAR
44
3
MU
40
-7
Financhill
Back

Phathom Pharmaceuticals Quote, Financials, Valuation and Earnings

Free Report: The Secret Backdoor to OpenAI and ChatGPT

Click here to download it for free with no strings attached.
Buy
52

PHAT
Phathom Pharmaceuticals

Last Price:
7.13
Seasonality Move:
1.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Debunked: One Of Wall Street's Biggest Myths!

Click here to keep reading

Phathom Pharmaceuticals Price Quote

$7.13
-0.01 (4.85%)
(Updated: April 1, 2023 at 5:25 AM ET)

Phathom Pharmaceuticals Key Stats

Buy
52
Phathom Pharmaceuticals (PHAT) is a Buy
Day range:
$6.78 - $7.16
52-week range:
$5.84 - $16.07
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%
Volume:
349.6K
Avg. volume:
351K
1-year change:
-47.54%
Market cap:
$299.7M
Revenue:
$0
EPS:
$-5.05

How Much Does Phathom Pharmaceuticals Make?

Data Unavailable

Is Phathom Pharmaceuticals Growing As A Company?

Data Unavailable

Phathom Pharmaceuticals Stock Price Performance

What Is Phathom Pharmaceuticals 52-Week High & Low?

Phathom Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Phathom Pharmaceuticals?

Is Phathom Pharmaceuticals Cash Flow Positive?

  • What Is PHAT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$146.5M
  • What Is Phathom Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $120M
  • What Is Phathom Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1M

Phathom Pharmaceuticals Return On Invested Capital

Data Unavailable

Phathom Pharmaceuticals Earnings Date & Stock Price

Phathom Pharmaceuticals Competitors

Phathom Pharmaceuticals Dividend Yield

Data Unavailable

Phathom Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.68%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 16.40
Upside from Last Price: 129.69%

Major Shareholders

  • How many PHAT shares are owned by institutional investors?
    32.2M PHAT shares are owned by institutional investors
  • How many PHAT shares are owned by insiders?
    2.7M PHAT shares are owned by insiders